The Medical Research Council (MRC) has today announced a £50 million investment in the new MRC Centre of Research Excellence in Mitochondrial Genome Therapeutics, which aims to enable new treatments i...

Primary mitochondrial diseases (PMD) arise from variants in the mitochondrial or nuclear genomes. Phenotype-based recognition of specific PMD genotypes remains difficult, prolonging the diagnostic ody...

This is a unique opportunity to carry out a period of clinical postdoctoral research focused on developing and validating new treatments and biomarkers for mitochondrial disorders, as part of a new

Rare disease research faces unique challenges including lack of investment, small patient populations, fragmented research and challenging routes to…